{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T02:13:02Z","timestamp":1788401582660,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014588","name":"Sanofi Pasteur SA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014588","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.vaccine.2026.128582","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T16:44:53Z","timestamp":1776444293000},"page":"128582","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Immunogenicity and safety of recombinant influenza vaccine versus standard inactivated influenza vaccine in children aged 3 to 8\u00a0years: results from a phase III randomised study"],"prefix":"10.1016","volume":"82","author":[{"given":"Pedro M.","family":"Folegatti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Pepin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Tabar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Fries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oxana","family":"Talanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"See","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Kaas-Leach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"De Bruijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.vaccine.2026.128582_bb0005","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1001\/jamapediatrics.2015.1387","article-title":"Influenza A virus infection, innate immunity, and childhood","volume":"169","author":"Coates","year":"2015","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.vaccine.2026.128582_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104970","article-title":"Burden of influenza B virus infection and considerations for clinical management","volume":"185","author":"Zaraket","year":"2021","journal-title":"Antiviral Res"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128582_bb0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001977","article-title":"Global role and burden of influenza in pediatric respiratory hospitalizations, 1982-2012: a systematic analysis","volume":"13","author":"Lafond","year":"2016","journal-title":"PLoS Med"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128582_bb0020","volume":"154","year":"2024","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2026.128582_bb0025","unstructured":"FluView Interactive. Available at: https:\/\/www.cdc.gov\/fluview\/overview\/fluview-interactive.html."},{"key":"10.1016\/j.vaccine.2026.128582_bb0030","series-title":"ECDC Surveillance report - Seasonal influenza, 2023\u20132024","year":"2024"},{"key":"10.1016\/j.vaccine.2026.128582_bb0035","unstructured":"WHO - Global Influenza Programme. Available at: https:\/\/www.who.int\/teams\/global-influenza-programme\/vaccines."},{"issue":"2","key":"10.1016\/j.vaccine.2026.128582_bb0040","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1093\/cid\/ciab931","article-title":"Vaccine effectiveness against life-threatening influenza illness in US children","volume":"75","author":"Olson","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128582_bb0045","article-title":"Cost-effectiveness of influenza vaccination in healthy children: a 10-year population-based study","volume":"12","author":"Barbieri","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2026.128582_bb0050","unstructured":"Weekly epidemiological record. Available at: https:\/\/www.who.int\/publications\/i\/item\/who-wer9719. Accessed December 2024."},{"key":"10.1016\/j.vaccine.2026.128582_bb0055","unstructured":"Seasonal Influenza - Vaccination and treatment. Available at: https:\/\/www.ecdc.europa.eu\/en\/seasonal-influenza."},{"key":"10.1016\/j.vaccine.2026.128582_bb0060","doi-asserted-by":"crossref","unstructured":"Grohskopf LA FJ, Blanton LH, Broder KR, Loehr J. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices \u2014 United States, 2024\u201325 Influenza Season. Available at: http:\/\/dx.doi.org\/10.15585\/mmwr.rr7305a1. Accessed December.","DOI":"10.15585\/mmwr.rr7305a1"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128582_bb0065","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41541-021-00403-7","article-title":"Unique features of a recombinant haemagglutinin influenza vaccine that influence vaccine performance","volume":"6","author":"Arunachalam","year":"2021","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2026.128582_bb0070","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S1473-3099(25)00153-7","article-title":"Comparative assessment of immunogenicity and safety of recombinant influenza vaccine in children, adolescents, and adults: results from a phase 3, immunobridging, open-label, non-randomised study","volume":"25","author":"Folegatti","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128582_bb0075","unstructured":"WHO. Recommendations announced for influenza vaccine composition for the 2023-2024 northern hemisphere influenza season. Available at: https:\/\/www.who.int\/publications\/m\/item\/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2023-2024-northern-hemisphere-influenza-season."},{"issue":"7","key":"10.1016\/j.vaccine.2026.128582_bb0080","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1093\/cid\/ciz1034","article-title":"Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial","volume":"71","author":"Cowling","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128582_bb0085","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1093\/cid\/ciab566","article-title":"Comparison of the immunogenicity of cell culture-based and recombinant quadrivalent influenza vaccines to conventional egg-based quadrivalent influenza vaccines among healthcare personnel aged 18-64 years: a randomized open-label trial","volume":"73","author":"Dawood","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128582_bb0090","unstructured":"Global Influenza Programme. Accessed 09 June."},{"issue":"6","key":"10.1016\/j.vaccine.2026.128582_bb0095","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/INF.0000000000002610","article-title":"Comparative severity of influenza A and B infections in hospitalized children","volume":"39","author":"Mattila","year":"2020","journal-title":"Pediatr Infect Dis J"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128582_bb0100","doi-asserted-by":"crossref","first-page":"44","DOI":"10.5409\/wjcp.v9.i3.44","article-title":"Influenza B infections in children: a review","volume":"9","author":"Bhat","year":"2020","journal-title":"World J Clin Pediatr"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128582_bb0105","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2024.2421096","article-title":"Seasonal influenza vaccines: variability of immune responses to B lineage viruses","volume":"20","author":"Miller","year":"2024","journal-title":"Hum Vaccin Immunother"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128582_bb0110","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1097\/INF.0b013e3182367662","article-title":"Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children","volume":"30","author":"Black","year":"2011","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128582_bb0115","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/infdis\/jiae122","article-title":"Hemagglutination inhibition antibody titers as mediators of influenza vaccine efficacy against symptomatic influenza A(H1N1), A(H3N2), and B\/Victoria virus infections","volume":"230","author":"Lim","year":"2024","journal-title":"J Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128582_bb0120","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/infdis\/jit372","article-title":"Estimation of the association between antibody titers and protection against confirmed influenza virus infection in children","volume":"208","author":"Ng","year":"2013","journal-title":"J Infect Dis"},{"issue":"47","key":"10.1016\/j.vaccine.2026.128582_bb0125","doi-asserted-by":"crossref","first-page":"6589","DOI":"10.1016\/j.vaccine.2009.08.032","article-title":"Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months","volume":"27","author":"King","year":"2009","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128582_bb0130","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2017-3021","article-title":"Safety and immunogenicity of a recombinant influenza vaccine: a randomized trial","volume":"141","author":"Dunkle","year":"2018","journal-title":"Pediatrics"},{"issue":"24","key":"10.1016\/j.vaccine.2026.128582_bb0135","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1056\/NEJMoa2302099","article-title":"Recombinant or standard-dose influenza vaccine in adults under 65 years of age","volume":"389","author":"Hsiao","year":"2023","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128582_bb0140","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1093\/infdis\/jix478","article-title":"Randomized comparison of immunogenicity and safety of quadrivalent recombinant versus inactivated influenza vaccine in healthy adults 18\u201349 years of age","volume":"216","author":"Dunkle","year":"2017","journal-title":"J Infect Dis"},{"issue":"25","key":"10.1016\/j.vaccine.2026.128582_bb0145","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa1608862","article-title":"Efficacy of recombinant influenza vaccine in adults 50 years of age or older","volume":"376","author":"Dunkle","year":"2017","journal-title":"N Engl J Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26003907?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26003907?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T20:54:34Z","timestamp":1782248074000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26003907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":29,"alternative-id":["S0264410X26003907"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128582","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity and safety of recombinant influenza vaccine versus standard inactivated influenza vaccine in children aged 3 to 8\u00a0years: results from a phase III randomised study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128582","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128582"}}